Convection-Enhanced Delivery for Neurodegeneration

Convection-Enhanced Delivery for Neurodegeneration

Overview

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">Convection-Enhanced Delivery for Neurodegeneration</th>
</tr>
<tr>
<td class="label">Category</td>
<td>Drug Delivery Technology</td>
</tr>
<tr>
<td class="label">Target</td>
<td>Brain tumors, Parkinson's, Alzheimer's, ALS</td>
</tr>
<tr>
<td class="label">Mechanism</td>
<td>Bulk flow infusion under pressure for distributed drug delivery</td>
</tr>
<tr>
<td class="label">Status</td>
<td>Clinical Trials (Phase I/II)</td>
</tr>
<tr>
<td class="label">Factor</td>
<td>Convection-Enhanced</td>
</tr>
<tr>
<td class="label">Distribution</td>
<td>Pressure-driven bulk flow</td>
</tr>
<tr>
<td class="label">Volume</td>
<td>Predictable, scalable</td>
</tr>
<tr>
<td class="label">Molecular weight</td>
<td>All sizes</td>
</tr>
<tr>
<td class="label">Time</td>
<td>Hours to days</td>
</tr>
<tr>
<td class="label">Coverage</td>
<td>1-10 cm³ per catheter</td>
</tr>
<tr>
<td class="label">Application</td>
<td>Agent</td>
</tr>
<tr>
<td class="label">Neurotrophic factor delivery</td>
<td>GDNF</td>
</tr>
<tr>
<td class="label">Neurotrophic factor delivery</td>
<td>AAV-GDNF</td>
</tr>
<tr>
<td class="label">Gene therapy</td>
<td>AAV-AADC</td>
</tr>
<tr>
<td class="label">Study</td>
<td>Year</td>
</tr>
<tr>
<td class="label">Gill et al.</td>
<td>2003</t

Convection-Enhanced Delivery for Neurodegeneration

Overview

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">Convection-Enhanced Delivery for Neurodegeneration</th>
</tr>
<tr>
<td class="label">Category</td>
<td>Drug Delivery Technology</td>
</tr>
<tr>
<td class="label">Target</td>
<td>Brain tumors, Parkinson's, Alzheimer's, ALS</td>
</tr>
<tr>
<td class="label">Mechanism</td>
<td>Bulk flow infusion under pressure for distributed drug delivery</td>
</tr>
<tr>
<td class="label">Status</td>
<td>Clinical Trials (Phase I/II)</td>
</tr>
<tr>
<td class="label">Factor</td>
<td>Convection-Enhanced</td>
</tr>
<tr>
<td class="label">Distribution</td>
<td>Pressure-driven bulk flow</td>
</tr>
<tr>
<td class="label">Volume</td>
<td>Predictable, scalable</td>
</tr>
<tr>
<td class="label">Molecular weight</td>
<td>All sizes</td>
</tr>
<tr>
<td class="label">Time</td>
<td>Hours to days</td>
</tr>
<tr>
<td class="label">Coverage</td>
<td>1-10 cm³ per catheter</td>
</tr>
<tr>
<td class="label">Application</td>
<td>Agent</td>
</tr>
<tr>
<td class="label">Neurotrophic factor delivery</td>
<td>GDNF</td>
</tr>
<tr>
<td class="label">Neurotrophic factor delivery</td>
<td>AAV-GDNF</td>
</tr>
<tr>
<td class="label">Gene therapy</td>
<td>AAV-AADC</td>
</tr>
<tr>
<td class="label">Study</td>
<td>Year</td>
</tr>
<tr>
<td class="label">Gill et al.</td>
<td>2003</td>
</tr>
<tr>
<td class="label">Lang et al.</td>
<td>2006</td>
</tr>
<tr>
<td class="label">Marks et al.</td>
<td>2010</td>
</tr>
</table>

Introduction

Convection-Enhanced Delivery (CED) is an advanced technique for delivering therapeutic agents directly into brain tissue by applying hydrostatic pressure to create bulk flow. This method overcomes the limitations of diffusion-based delivery, enabling uniform distribution of large molecules, nanoparticles, and genes throughout targeted brain regions.

Technical Principles

Mechanism of Action

CED uses the following principle:

Comparison with Diffusion

Clinical Applications

Parkinson's Disease

Alzheimer's Disease

• Anti-amyloid antibodies (e.g., aducanumab, lecanemab)
• Anti-[tau](/proteins/tau) therapies
• Neurotrophic factors (BDNF, NGF)
• Gene therapy vectors

ALS

• Antisense oligonucleotides
• Neurotrophic factors
• VEGF delivery
• Stem cells

Brain Tumors

• Chemotherapy agents (e.g., paclitaxel, topotecan)
• Immunotoxins
• Viral vectors

Equipment and Technique

Catheter Systems

Infusion Parameters

• Pressure: 5-100 mmHg
• Rate: 0.5-10 μL/min (typically 1-5 μL/min)
• Volume: 0.5-10 mL per infusion
• Duration: 4-48 hours per treatment

Imaging Guidance

• MRI - Real-time visualization with gadolinium
• CT - Anatomical planning
• PET - Target verification

Advantages

Challenges and Limitations

Technical Challenges

Safety Concerns

Clinical Evidence

Parkinson's Disease Trials

Current Trials

• CED of AAV-GDNF for advanced PD
• CED of AADC gene therapy for PD
• CED of topotecan for gliomas

Future Directions

Emerging Applications

Technology Improvements

See Also

• [Blood-Brain Barrier](/mechanisms/blood-brain-barrier)
• [Parkinson's Disease](/diseases/parkinsons-disease)
• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [GDNF Therapy](/therapeutics/gdnf-therapy-parkinsons)
• [Gene Therapy](/therapeutics/gene-therapy)
• [Intranasal Therapy](/therapeutics/intranasal-therapy-neurodegeneration)

Background

The study of Convection Enhanced Delivery For Neurodegeneration has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.

Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.

Allen Brain Atlas Resources

• [Allen Brain Atlas - Gene Expression](https://human.brain-map.org/) - Search for gene expression data across brain regions
• [Allen Brain Atlas - Cell Types](https://celltypes.brain-map.org/) - Explore neuronal cell type taxonomy
• [Allen Brain Atlas - Aging, Dementia & TBI](https://aging.brain-map.org/) - Data on aging and traumatic brain injury

External Links

• [NIH - CED Research](https://www.nih.gov/)
• [Parkinson's Foundation](https://www.parkinson.org/)
• [American Brain Tumor Association](https://www.abta.org/)

References

Related Hypotheses

From the [SciDEX Exchange](/exchange) — scored by multi-agent debate

• [Nutrient-Sensing Epigenetic Circuit Reactivation](/hypothesis/h-4bb7fd8c) — <span style="color:#81c784;font-weight:600">0.79</span> · Target: SIRT1
• [CYP46A1 Overexpression Gene Therapy](/hypothesis/h-2600483e) — <span style="color:#81c784;font-weight:600">0.79</span> · Target: CYP46A1
• [Circadian Glymphatic Entrainment via Targeted Orexin Receptor Modulation](/hypothesis/h-9e9fee95) — <span style="color:#81c784;font-weight:600">0.77</span> · Target: HCRTR1/HCRTR2
• [Selective Acid Sphingomyelinase Modulation Therapy](/hypothesis/h-de0d4364) — <span style="color:#81c784;font-weight:600">0.77</span> · Target: SMPD1
• [Membrane Cholesterol Gradient Modulators](/hypothesis/h-9d29bfe5) — <span style="color:#81c784;font-weight:600">0.76</span> · Target: ABCA1/LDLR/SREBF2
• [Microbial Inflammasome Priming Prevention](/hypothesis/h-e7e1f943) — <span style="color:#81c784;font-weight:600">0.76</span> · Target: NLRP3, CASP1, IL1B, PYCARD
• [Blood-Brain Barrier SPM Shuttle System](/hypothesis/h-959a4677) — <span style="color:#81c784;font-weight:600">0.75</span> · Target: TFRC
• [Purinergic Signaling Polarization Control](/hypothesis/h-0758b337) — <span style="color:#81c784;font-weight:600">0.74</span> · Target: P2RY1 and P2RX7

• [Selective vulnerability of entorhinal cortex layer II neurons in AD](/analysis/SDA-2026-04-01-gap-004) &#x1f504;
• [4R-tau strain-specific spreading patterns in PSP vs CBD](/analysis/SDA-2026-04-01-gap-005) &#x1f504;
• [TDP-43 phase separation therapeutics for ALS-FTD](/analysis/SDA-2026-04-01-gap-006) &#x1f504;
• [Astrocyte reactivity subtypes in neurodegeneration](/analysis/SDA-2026-04-01-gap-007) &#x1f504;
• [Blood-brain barrier transport mechanisms for antibody therapeutics](/analysis/SDA-2026-04-01-gap-008) &#x1f504;